Moderna Inc (MRNA.O) will sell around $604.3 million in shares in its initial public offering (IPO), the biotech company said on Thursday, braving stock market jitters to sell more stock than originally planned. In the...
AstraZeneca-Backed ADC Therapeutics Weighs IPO, Sale
ADC Therapeutics SA, a Swiss biotechnology company whose backers include U.K. drugmaker AstraZeneca Plc, is in the early stages of exploring options, including an initial public offering, amid growing interest in...
Chinese biotech firm Ascletis raises $400 million in HK IPO: sources
Chinese biotech Ascletis Pharma Inc (1672.HK) raised $400 million after pricing its IPO in the middle of an indicative range, three people said, in the first such Hong Kong listing under rules designed to attract early...
Bankruptcy court admits lenders insolvency plea against Sterling Biotech
The bankruptcy court has admitted the insolvency plea against Sterling BiotechNSE -3.33 % filed by Andhra Bank – a move by banks to recover their dues amidst probe by investigative agencies on allegation of misuse of...
Fujifilm to buy two biotech units from JXTG for $800 million
Fujifilm Holdings said it would buy two biotechnology units of Japan’s JXTG Holdings Inc for about $800 million, as it looks to boost its healthcare business. Fujifilm is seeking growth through buying businesses...
Biotech M&A explodes with $27.5 billion of January deals
Biotech deal-making is the hottest in more than a decade with $27.5 billion of transactions agreed this month and bankers reporting an above-average number of discussions that could lead to fresh activity through 2018...
Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom
French drugmaker Sanofi has agreed to buy Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion), beating Novo Nordisk and marking its second big deal this month after buying Bioverativ. The transaction is...
Biotech M&A takes off as Sanofi and Celgene spend $20 billion
Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for haemophilia and cancer to their medicine cabinets...
J&J discussing breaking up Actelion in an acquisition – sources
Johnson & Johnson (JNJ.N) is negotiating a deal to acquire Swiss biotechnology company Actelion Ltd (ATLN.S) that would separate its commercialized portfolio from its research and development assets, people familiar...
Actelion re-enters talks with J&J, sidelining Sanofi
Swiss biotech company Actelion (ATLN.S) has turned back to prospective bidder Johnson & Johnson (JNJ.N) for exclusive talks about a “strategic transaction”, in an about-turn that appears to sideline...
OMCs shut biodiesel joint ventures due to lack of commercial viability
Mumbai: Once touted as the fuel of the future, biodiesel, extracted from jatropha seeds, has lost its sheen for oil marketing companies. Due to lack of availability and commercial viability, the three oil marketing...
Carlyle Group emerges front-runner for Bharat Biotech stake
The world’s second-largest private equity fund, the Carlyle Group, which ranks India as the most attractive global investment destination has emerged as the front-runner to buy out the stakes of three PE investors...
